4.8 Article

Glycopeptide-specific monoclonal antibodies suggest new roles for O-GlcNAc

Journal

NATURE CHEMICAL BIOLOGY
Volume 6, Issue 5, Pages 338-343

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nchembio.338

Keywords

-

Funding

  1. US National Institute of Diabetes and Digestive and Kidney [NIH RO1 DK075069]
  2. Research Resource for Integrated Glycotechnology [NIH/NCRR P41R005351]
  3. National Cancer Institute of the US National Institutes of Health [NIH/NCI R01CA088986, NIH HL067464, HL079364]
  4. American Heart Association (Southeast Affiliation)

Ask authors/readers for more resources

Studies of post-translational modification by beta-N-acetyl-D-glucosamine (O-GlcNAc) are hampered by a lack of efficient tools such as O-GlcNAc-specific antibodies that can be used for detection, isolation and site localization. We have obtained a large panel of O-GlcNAc-specific IgG monoclonal antibodies having a broad spectrum of binding partners by combining three-component immunogen methodology with hybridoma technology. Immunoprecipitation followed by large-scale shotgun proteomics led to the identification of more than 200 mammalian O-GlcNAc-modified proteins, including a large number of new glycoproteins. A substantial number of the glycoproteins were enriched by only one of the antibodies. This observation, combined with the results of inhibition ELISAs, suggests that the antibodies, in addition to their O-GlcNAc dependence, also appear to have different but overlapping local peptide determinants. The monoclonal antibodies made it possible to delineate differentially modified proteins of liver in response to trauma-hemorrhage and resuscitation in a rat model.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available